Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein. 1978

J J Albers, and G R Warnick, and D Wiebe, and P King, and P Steiner, and L Smith, and C Breckenridge, and A Chow, and K Kuba, and S Weidman, and H Arnett, and P Wood, and A Shlagenhaft

Plasma high-density lipoprotein is commonly estimated by measuring the cholesterol remaining in plasma supernatant solutions after other lipoproteins, which contain apolipoprotein B, are precipitated with heparin and Mn2+. The method (method I) now in use by the Lipid Research Clinics, in which Mn2+ is at 46 mmol/liter final concentration, is reasonably accurate, but precipitation and sedimentation of lipoproteins other than high-density lipoproteins is often incomplete. We evaluated two modifications of method I. In method II, the Mn2+ concentration was doubled; the second modification (method III) included the increased Mn2+ concentration in a combined heparin Mn2+ reagent, decreased sample volume (2 ml), and a shorter incubation time (10 min at room temperature). The percentages of samples with turbid supernates (i.e., incomplete sedimentation) by methods I, II, and III were 9, 3, and 2%, respectively. Among non-turbid supernates, the percentages of samples containing measurable apolipoprotein B (incomplete precipitation) were 79, 19, and 16%, respectively. We conclude that method III is the most convenient and accurate of the three procedures.

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008345 Manganese A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035)
D008722 Methods A series of steps taken in order to conduct research. Techniques,Methodological Studies,Methodological Study,Procedures,Studies, Methodological,Study, Methodological,Method,Procedure,Technique
D011232 Chemical Precipitation The formation of a solid in a solution as a result of a chemical reaction or the aggregation of soluble substances into complexes large enough to fall out of solution. Precipitation, Chemical
D011786 Quality Control A system for verifying and maintaining a desired level of quality in a product or process by careful planning, use of proper equipment, continued inspection, and corrective action as required. (Random House Unabridged Dictionary, 2d ed) Control, Quality,Controls, Quality,Quality Controls
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J J Albers, and G R Warnick, and D Wiebe, and P King, and P Steiner, and L Smith, and C Breckenridge, and A Chow, and K Kuba, and S Weidman, and H Arnett, and P Wood, and A Shlagenhaft
March 1980, Annals of clinical biochemistry,
J J Albers, and G R Warnick, and D Wiebe, and P King, and P Steiner, and L Smith, and C Breckenridge, and A Chow, and K Kuba, and S Weidman, and H Arnett, and P Wood, and A Shlagenhaft
May 1977, Clinical chemistry,
J J Albers, and G R Warnick, and D Wiebe, and P King, and P Steiner, and L Smith, and C Breckenridge, and A Chow, and K Kuba, and S Weidman, and H Arnett, and P Wood, and A Shlagenhaft
August 1980, Clinical chemistry,
J J Albers, and G R Warnick, and D Wiebe, and P King, and P Steiner, and L Smith, and C Breckenridge, and A Chow, and K Kuba, and S Weidman, and H Arnett, and P Wood, and A Shlagenhaft
February 1983, Clinica chimica acta; international journal of clinical chemistry,
J J Albers, and G R Warnick, and D Wiebe, and P King, and P Steiner, and L Smith, and C Breckenridge, and A Chow, and K Kuba, and S Weidman, and H Arnett, and P Wood, and A Shlagenhaft
June 1984, Clinical biochemistry,
J J Albers, and G R Warnick, and D Wiebe, and P King, and P Steiner, and L Smith, and C Breckenridge, and A Chow, and K Kuba, and S Weidman, and H Arnett, and P Wood, and A Shlagenhaft
June 1984, Clinical chemistry,
J J Albers, and G R Warnick, and D Wiebe, and P King, and P Steiner, and L Smith, and C Breckenridge, and A Chow, and K Kuba, and S Weidman, and H Arnett, and P Wood, and A Shlagenhaft
January 1978, Clinical chemistry,
J J Albers, and G R Warnick, and D Wiebe, and P King, and P Steiner, and L Smith, and C Breckenridge, and A Chow, and K Kuba, and S Weidman, and H Arnett, and P Wood, and A Shlagenhaft
May 1981, Clinica chimica acta; international journal of clinical chemistry,
J J Albers, and G R Warnick, and D Wiebe, and P King, and P Steiner, and L Smith, and C Breckenridge, and A Chow, and K Kuba, and S Weidman, and H Arnett, and P Wood, and A Shlagenhaft
January 1981, Annales de biologie clinique,
J J Albers, and G R Warnick, and D Wiebe, and P King, and P Steiner, and L Smith, and C Breckenridge, and A Chow, and K Kuba, and S Weidman, and H Arnett, and P Wood, and A Shlagenhaft
February 1985, Clinical chemistry,
Copied contents to your clipboard!